---
input_text: Differential response to renal replacement therapy in neonatal-onset inborn
  errors of metabolism. Severe urea cycle defects (UCD), organic acidemias (OA) and
  maple syrup urine disease (MSUD) are life-threatening disorders presenting in the
  first days of life. Renal replacement therapy (RRT) is an emergency option in affected
  newborns, mostly performed as ultima ratio. We report our 10-year experience using
  emergency RRT in newborns with UCD, OA and MSUD. Twelve newborns (eight with UCD,
  two with methylmalonic acidemia and two with MSUD) underwent emergency RRT. The
  overall survival rate to RRT was 58.3%. Hyperammonemic newborns required earlier
  RRT with respect to MSUD patients (75 (65-102) vs 301 (192-410) h of life, P < 0.01).
  Hyperammonemic neonates surviving (n = 5) and non-surviving (n = 5) the acute neonatal
  decompensation showed similar birth weight (P = 0.690), duration of intubation (P
  = 0.917), ammonia at onset (P = 0.916) and at the start of RRT (P = 0.426), age
  at RRT (P = 0.999) and duration of coma before RRT (P = 0.691). Remarkably, all
  survivors quickly responded to RRT, with ammonia concentration less than 300 mumol/L
  after 8 h of treatment. One patient with UCD successfully treated by neonatal RRT
  died at 4 months of life because of sepsis. All patients with MSUD had normalized
  leucine levels after 12 h of RRT, surviving the acute neonatal decompenstation.
  All long-term survivors (five liver transplanted, one waiting for liver transplantation)
  currently show normal or near-normal neurological development (48 +- 39 months of
  age). Early response to RRT was associated with survival irrespective of pre-treatment
  picture. RRT can be considered even in huge neonatal metabolic decompensations.
  Early liver transplantation may be an option for select patients.
raw_completion_output: |-
  primary_disease: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease (MSUD)>
  medical_actions: <renal replacement therapy (RRT); liver transplantation>
  symptoms: <hyperammonemia; elevated ammonia levels; coma; neonatal decompensation; elevated leucine levels>
  chemicals: <>
  action_annotation_relationships: <renal replacement therapy (RRT) TREATS hyperammonemia IN Urea cycle defects (UCD); renal replacement therapy (RRT) TREATS elevated ammonia levels IN Urea cycle defects (UCD); renal replacement therapy (RRT) TREATS neonatal decompensation IN organic acidemias (OA); renal replacement therapy (RRT) TREATS neonatal decompensation IN maple syrup urine disease (MSUD); renal replacement therapy (RRT) TREATS elevated leucine levels IN maple syrup urine disease (MSUD); liver transplantation PREVENTS neonatal decompensation IN Urea cycle defects (UCD); liver transplantation PREVENTS neonatal decompensation IN organic acidemias (OA); liver transplantation PREVENTS neonatal decompensation IN maple syrup urine disease (MSUD)>
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  liver transplantation PREVENTS neonatal decompensation IN maple syrup urine disease (MSUD)>

  ===

extracted_object:
  primary_disease: MONDO:0004739
  medical_actions:
    - MAXO:0000600
    - liver transplantation>
  symptoms:
    - <hyperammonemia
    - HP:0001987
    - HP:0001259
    - neonatal decompensation
    - elevated leucine levels>
  chemicals:
    - <>
  action_annotation_relationships:
    - subject: MAXO:0000600
      predicate: TREATS
      object: HP:0001987
      qualifier: MONDO:0004739
    - subject: MAXO:0000600
      predicate: TREATS
      object: HP:0001987
      qualifier: MONDO:0004739
    - subject: MAXO:0000600
      predicate: TREATS
      object: neonatal decompensation
      qualifier: MONDO:0000688
    - subject: MAXO:0000600
      predicate: TREATS
      object: neonatal decompensation
      qualifier: MONDO:0009563
    - subject: MAXO:0000600
      predicate: TREATS
      object: elevated leucine levels
      qualifier: MONDO:0009563
    - subject: MAXO:0001175
      predicate: PREVENTS
      object: neonatal decompensation
      qualifier: MONDO:0004739
    - subject: MAXO:0001175
      predicate: PREVENTS
      object: neonatal decompensation
      qualifier: MONDO:0008143
    - subject: MAXO:0001175
      predicate: PREVENTS
      object: neonatal decompensation
      qualifier: MONDO:0009563
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
